The FDA is, of course, unaware that a decision on the earlier readout is important to ADXS for business reasons. And they wouldn’t care anyway. Not that it has ever done anything in an efficient manner for ADXS anyway. Champion foot draggers.
Although it’s possible that the FDA approval for the interim look can provide some boost and is the showstopper for any AXAL deal, I doubt it is the reason for an absence of any monetary deals. They had lots of time to strike a deal and it has not happened. The reason could be as simple as there was no Ph 2 for the adjuvant settings. Now it’s a crapshoot for any pharma to pay for it. Well, they could have taken a stake in the company but why would they do that? Advaxis is on life support and they know it. Too much risk for unknown payoff. I don’t have to talk about the ISTs as they are virtually irrelevant to the direction of this company.
James, while I also think it's important we get FDA nod, I don't see it as holding up other deals. Ken said they were in discussions with Merck for a path forward for PSA as well as other potential partners. I would, however, rest easier if the FDA would give their blessing. It seems to be taking an inordinate amount of time.
News 
Market Data 
Discover 
